市场调查报告书
商品编码
1184255
血管贴片全球市场规模、份额、行业趋势分析报告:按材料(生物/合成)、最终用户(医院/门诊手术中心)、应用和地区预测2022-2028Global Vascular Patches Market Size, Share & Industry Trends Analysis Report By Material (Biologic and Synthetic), By End User (Hospitals and Ambulatory Surgical Centers), By Application, By Regional Outlook and Forecast, 2022 - 2028 |
全球血管贴片市场规模预计将在 2028 年达到 5.29 亿美元,预测期内復合年增长率为 7.1%。
血管外科具有许多与其他临床领域不同的特点。 虽然大多数血管手术都是干净的,但频繁使用人工移植物通常会增加感染的可能性。 此外,接受血管手术的患者通常年龄较大,并且更有可能患有许多疾病,例如糖尿病、免疫系统减弱、免疫紊乱、高血压和心脏病。
在胰腺或肾臟移植的情况下,不仅是移植器官,而且接受者的生命和四肢都可能因感染性血管疾病而受到威胁。 这种严重的血管疾病可能需要復杂的血管修復或血管切除术。 血管疾病患病率上升、老年人口迅速增加、生物补片流行、血管手术数量增加等是推动全球血管补片市场的因素。
COVID-19 影响分析
除了与 COVID-19 相关的后遗症外,患者入院延迟和急诊资源转移对接受血管手术的患者的健康也有重大影响。 儘管在 COVID-19 手术室法规的应用、个人防护设备 (PPE) 的可用性或遵守国家手术标准方面没有地区差异,但许多手术已被取消或有选择地推迟。稻田。 由于大流行,获得血管外科服务和患者的机会受到严重限制。 血管治疗以与以往完全不同的方式进行。 许多门诊诊所和门诊血管外科医生报告了实践中的变化,包括获得远程医疗服务和缩短咨询时间。 对住院服务的影响同样显着。
市场增长因素
不断增长的老年人口和不断增加的血管疾病患病率
CVD、高血压、高血脂、中风、癌症、动脉瘤等各种疾病发病率不断上升的主要原因之一是全球老龄化人口的迅速膨胀。这是因为 人口老龄化被认为是心臟健康状况下降的主要因素,因此使其成为市场增长的关键预测指标。 世界卫生组织预测,到 2030 年,世界上六分之一的人将超过 60 岁。
血管治疗的报销选项
血管外科医生在手术期间在支持其他外科专家方面发挥着重要作用。 这种手术支持的频率和经济价值大,贡献和边际贡献率也大。 作为顾问医师,血管外科医生还通过解决极其复杂的病例为医院增加了显着的经济价值。 患者的第一个特点是患有多种疾病。 这意味着同时患有两种或多种慢性病。
市场约束
对合格人员的需求增加。
血管补片应由熟练人员处理,因为手术后动脉闭合不充分会导致持续出血和缺血。 此外,在使用小工具时,许多操作必须按顺序执行。 目前阻碍其传播的是发达国家和新兴国家外科医生的短缺。 例如,根据美国医学院协会 (AAMC) 的数据,到 2032 年,美国预计将缺少 122,000 名医生。
材料展望
按材料划分,市场分为生物材料和合成材料。 2021年血管贴片的市场份额将是生物血管贴片最大的,主要是因为其易于应用、术后感染风险低、生物相容性高。 生物血管补片的可生物降解质量和更高的拉伸强度和缝线保持强度是其两个主要优势。
应用展望
根据应用,市场已细分为颈动脉内膜切除术、腹动脉瘤开放修復术、血管旁路手术、先天性心脏病等。 到 2021 年,颈动脉内膜切除术将占据市场最大的收入份额。 为了缓解颈动脉狭窄并降低中风的风险,必须在称为颈动脉内膜切除术的手术中打开颈动脉。 当动脉在手术结束时闭合时,通过修补动脉开口可以降低中风的风险。
最终用户展望
根据最终用户,市场分为医院和门诊手术中心。 预计门诊手术中心将在预测期内见证最快的增长。 根据门诊手术中心协会的说法,门诊手术中心 (ASC) 是一种全新类型的医疗机构,旨在提供当日手术治疗,包括诊断和预防程序。
区域展望
按地域划分,分为北美、欧洲、亚太、LAMEA。 由于该地区老年人口不断增长和心血管疾病患病率高,预计北美将在全球血管贴片市场中占据领先地位。 例如,根据美国人口普查局2015年3月的一篇文章,该国的老年人口将从2014年的3.19亿增长到2060年的4亿多,到2051年预计将达到4亿。
The Global Vascular Patches Market size is expected to reach $529 Million by 2028, rising at a market growth of 7.1% CAGR during the forecast period.
Vascular patches are microporous polyester-urethane patches used in vascular procedures to close the wound with sutures. The World Health Organization (WHO) reports that cardiovascular diseases-which take 17.9 million lives annually-are the main cause of death. Vascular patches have great tissue integration, are highly biocompatible, have low infectious potential, low suture line bleeding, don't require impregnation or pre-clotting, and have good handling characteristics.
Due to the growing frequency of cardiac difficulties, technological advancements, and improvements in healthcare, the global market for vascular patches is anticipated to develop profitably in the years to come. A recent cross-disciplinary area of medical study is vascular surgery. Vascular surgeries are classed in that a range of artificial grafts (stents, stent-grafts, artificial blood vessels) are commonly used in clinical disciplines.
Vascular surgeries have many features with other clinical disciplines. Although most vascular surgical procedures are clean, the likelihood of infection is typically substantial since artificial grafts are frequently used. Additionally, patients undergoing vascular surgery are frequently elderly and are more likely to have a number of internal medical conditions, including diabetes, weak immune systems, immunological disorders, hypertension, and heart disease.
After pancreas or kidney transplantation, infectious vascular problems can put the recipient's life and limb, as well as the donated organ, in danger. These serious disorders can call for intricate vascular repair and vascular excision. The prevalence of vascular disorders is rising, the geriatric population is expanding quickly, biological patches are being more widely used, and there are more vascular surgeries being conducted, all of which are factors that are propelling the worldwide vascular patches market.
COVID-19 Impact Analysis
Patients delaying hospital exposure and diverting resources to urgent care have had a significant impact on the health of patients undergoing vascular surgery, in addition to COVID-19-related aftereffects. Despite no regional variation in the application of COVID-19 operating room rules, accessibility to personal protective equipment (PPE), or compliance with national surgical standards, many surgeries were either canceled or postponed electively. Vascular surgery services and patient access have been severely limited as a result of the pandemic. Vascular care is being delivered in a very different way. Many vascular surgeons who practice in outpatient clinics and ambulatory care reported that their practice has altered, including the use of telemedicine services and shorter hours. The impact on inpatient services was likewise significant.
Market Growth Factors
Increasing Geriatric Population And Rising Vascular Disease Prevalence
One of the main causes of the rising occurrence of various diseases and ailments, including CVDs, hypertension, high cholesterol, strokes, cancer, and aneurysms, is the rapidly expanding senior population worldwide. The aging population is a key predictor of market growth because it is thought that aging is a major factor in the decline of cardiac health. By 2030, one in every six people worldwide will be 60 years of age or older, predicts the WHO.
Reimbursement Options For Vascular Treatments
Vascular surgeons support other surgical specialties during operations in a crucial way. The frequency and financial worth of this operational support, which has a large contribution margin and contribution margin ratio, are substantial. Vascular surgeons, in their function as consulting surgeons, facilitate the resolution of extremely complex cases and, in doing so, add significantly to the hospital's financial value. The primary characteristic of patients is multi-morbidity. It denotes the concurrent presence of two or more chronic diseases.
Market Restraining Factors
Growing requirement for qualified personnel.
Vascular patches must be handled by skilled personnel since poor artery closure following surgery can result in ongoing bleeding or ischemia. While using some gadgets, many actions must be taken in order. One of the main barriers preventing the widespread use of these goods at the moment is the shortage of surgeons in both industrialized and emerging nations. For instance, the US is expected to experience a 122,000 physician deficit by 2032, according to the Association of American Medical Colleges (AAMC).
Material Outlook
Based on material, the market is classified into biologic and synthetic. The biologic vascular patch segment held the largest market share for vascular patches in 2021, mainly because it was easier to apply, had a lower risk of infection after surgery, and had greater biocompatibility. The biologic vascular patches' biodegradable quality and greater tensile and suture retention strength are two of their key advantages.
Application Outlook
Based on Applications, the market was categorized into Carotid Endarterectomy, Open Repair of Abdominal Aneurysm, Vascular Bypass Surgery, Congenital Heart Diseases, and Others. During 2021, carotid endarterectomy gained the largest revenue share in the market. In order to relieve this narrowing and so lower the risk of stroke, a procedure known as a carotid endarterectomy requires opening the carotid artery. The risk of strokes is decreased by placing a patch into the opening in the artery as the artery is closed at the end of the procedure.
End-user Outlook
Based on the End-user, the market is categorized into Hospitals and Ambulatory Surgical Centers. Ambulatory surgery centers are anticipated to experience the fastest growth during the forecasted timeframe. According to the ambulatory surgical center association, ambulatory surgery centers (ASCs) are a brand-new type of healthcare institution designed to provide same-day surgical treatment, including diagnostic and preventative procedures.
Regional Outlook
Based on geography, the market is classified into North America, Europe, Asia Pacific, and LAMEA. Due to the rising elderly population and the high prevalence of cardiovascular illnesses in the region, North America is predicted to have a leading position in the global market for vascular patches. For instance, a March 2015 article from the US Census Bureau states that the country's elderly population is projected to rise from 319 million in 2014 to more than 400 million in 2060, hitting 400 million in 2051.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Edwards Lifesciences Corporation, Baxter International, Inc., Lemaitre Vascular, Inc., Becton, Dickinson and Company, Terumo Corporation, Aziyo Biologics, Inc., Getinge AB, B. Braun Melsungen AG, Artivion, Inc. (CryoLife, Inc.), and W. L. Gore & Associates, Inc.
Strategies Deployed in Vascular Patches Market
Sep-2022: Edwards Lifesciences released the SAPIEN 3 Ultra RESILIA valve, a catheter-based artificial heart valve system consisting of RESILIA tissue technology. This launch shows the Company's effort in innovations to address the present and future requirements of patients to help them live healthier, longer, and more productive.
Sep-2022: W. L. Gore & Associates took over InnAVasc Medical, a small medical technology company. Through this acquisition, W. L. Gore & Associates would add InnAVasc's investigational technology to strengthen the company's plan to enhance patients' lives by delivering physicians-developed treatment solutions in dialysis access space.
Dec-2021: Becton, Dickinson, and Company completed the acquisition of Venclose, Inc., a medical technology company. Under this acquisition, Becton, Dickinson, and Company would broaden developments in the treatment of Chronic Venous Disease. Additionally, the acquisition would allow the company to offer a strong suite of solutions to physicians treating the complete extent of venous conditions.
Dec-2021: Baxter International Inc. completed the acquisition of Hillrom, a provider of medical technology. This acquisition would help Baxter in reaching another level of transformation, offering a new wave of ability to deliver better results for employees, shareholders, patients, and other parties whom the company serves globally.
Jan-2020: Terumo released New Surgical Sealant AQUABRID®, a new surgical sealant developed for aortic procedures, across the EMEA market. The product would deliver a new market for the business in a segment of growing importance for its business.
Oct-2019: LeMaitre Vascular, Inc. took over the biologic patch business of Admedus Ltd., a structural heart company engaged in offering clinically advanced solutions. The patches taken over by LeMaitre Vascular, Inc. are marketed under the brands VascuCel and CardioCel and are designed in a way to decrease the risk of calcification.
Apr-2019: Edwards Lifesciences Corporation took over CAS Medical Systems, Inc., a medical technology engaged in the monitoring of non-invasive brain and tissue oxygenation. Under This acquisition, Edwards would combine HemoSphere's advanced hemodynamic monitoring platform with FORE-SIGHT technology to build a specific suite of better recovery tools and abilities of predictive analytics for clinicians.
Oct-2018: LeMaitre Vascular Inc. acquired Cardial, a subsidiary of Becton, Dickinson & Company, a medical technology company. Under this acquisition, LeMaitre Vascular Inc. would broaden its global presence in the area of supporting vascular surgeons.
Market Segments covered in the Report:
By Material
By End User
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures